Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82.
利用新型 NAMPT 抑制剂 OT-82 靶向 FH 缺陷型遗传性平滑肌瘤病和肾细胞癌中的 NAD+ 代谢脆弱性
期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-24-0225
Najera Susana S, Ricketts Christopher J, Schmidt Laura S, Medina Julia I, Saito Keita, Ileva Lilia, Brender Jeffrey R, James Amy M, Peer Cody J, Gouker Brad, Karim Baktiar O, Chernova Olga, Wells Catherine, Wei Ming-Hui, Yang Youfeng, Zhang Xiaohu, Klumpp-Thomas Carleen, Travers Jameson, Chen Lu, Wilson Kelli M, Issaq Sameer H, Figg William D, Difilippantonio Simone, Kalen Joseph D, Krishna Murali C, Thomas Craig J, Ceribelli Michele, Heske Christine M, Crooks Daniel R, Meier Jordan L